Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2015’, provides an overview of the Neuromyelitis Optica (Devic’s Syndrome)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Neuromyelitis Optica (Devic’s Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuromyelitis Optica (Devic’s Syndrome) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devic’s Syndrome)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Neuromyelitis Optica (Devic’s Syndrome) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Neuromyelitis Optica (Devic’s Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Neuromyelitis Optica (Devic’s Syndrome) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Neuromyelitis Optica (Devic’s Syndrome) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Introduction
- Global Markets Direct Report Coverage
- Neuromyelitis Optica (Devic’s Syndrome) Overview
- Therapeutics Development
- Pipeline Products for Neuromyelitis Optica (Devic’s Syndrome) - Overview
- Pipeline Products for Neuromyelitis Optica (Devic’s Syndrome) - Comparative Analysis
- Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics under Development by Companies
- Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics under Investigation by Universities/Institutes
- Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Neuromyelitis Optica (Devic’s Syndrome) - Products under Development by Companies
- Neuromyelitis Optica (Devic’s Syndrome) - Products under Investigation by Universities/Institutes
- Neuromyelitis Optica (Devic’s Syndrome) - Companies Involved in Therapeutics Development
- Acorda Therapeutics, Inc.
- Alexion Pharmaceuticals, Inc.
- Chugai Pharmaceutical Co., Ltd.
- Genmab A/S
- HanAll Biopharma Co., Ltd.
- Karus Therapeutics Limited
- MedImmune, LLC
- Opexa Therapeutics, Inc.
- Shire Plc
- Takeda Pharmaceutical Company Limited
- Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- C1 esterase inhibitor (human) - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- dalfampridine ER - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Dendritic Cell Therapy for Central Nervous System Disorders - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Drugs to Inhibit Neutrophil Elastase for Neuromyelitis Optica - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- eculizumab - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- HL-161 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- immune globulin (human) - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- KA-1463 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MEDI-551 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ofatumumab - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- OPX-212 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SA-237 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Neuromyelitis Optica (Devic’s Syndrome) - Recent Pipeline Updates
- Neuromyelitis Optica (Devic’s Syndrome) - Dormant Projects
- Neuromyelitis Optica (Devic’s Syndrome) - Product Development Milestones
- Featured News & Press Releases
- Apr 20, 2015: Opexa Therapeutics Invited to Present Biomarker Data from NMO Patients at The American Academy of Neurology 2015 Annual Meeting
- Nov 25, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optica
- Sep 08, 2014: Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica as next Development Program
- May 30, 2014: Genmab Announces Ofatumumab Development Plans in RRMS and NMO
- Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis
- Dec 16, 2013: Soliris Concentrated Solution for Intravenous Infusion by Alexion: Recall - Visible Particles
- Dec 13, 2013: Alexion Provides Update on Previously Communicated November 2013 Voluntary Nationwide Recall of Two Lots of Soliris Concentrated Solution for Intravenous Infusion
- Jul 16, 2013: Alexion’s Soliris Receives Positive Opinion from the Committee for Orphan Medicinal Products for Treatment of Neuromyelitis Optica
- Jun 27, 2013: Alexion Pharma's Soliris Receives FDA Orphan Drug Designation For Treatment Of Neuromyelitis Optica
- Oct 09, 2012: Alexion Pharma Announces Presentation Of Phase II Study Data Of Eculizumab In Patients With Relapsing Neuromyelitis Optica At ANA Annual Meeting
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H2 2015
- Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome) - Comparative Analysis, H2 2015
- Number of Products under Development by Companies, H2 2015
- Number of Products under Investigation by Universities/Institutes, H2 2015
- Comparative Analysis by Late Stage Development, H2 2015
- Comparative Analysis by Clinical Stage Development, H2 2015
- Comparative Analysis by Early Stage Development, H2 2015
- Products under Development by Companies, H2 2015
- Products under Investigation by Universities/Institutes, H2 2015
- Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Acorda Therapeutics, Inc., H2 2015
- Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Alexion Pharmaceuticals, Inc., H2 2015
- Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2015
- Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Genmab A/S, H2 2015
- Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
- Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Karus Therapeutics Limited, H2 2015
- Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by MedImmune, LLC, H2 2015
- Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Opexa Therapeutics, Inc., H2 2015
- Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Shire Plc, H2 2015
- Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
- Assessment by Monotherapy Products, H2 2015
- Number of Products by Stage and Target, H2 2015
- Number of Products by Stage and Mechanism of Action, H2 2015
- Number of Products by Stage and Route of Administration, H2 2015
- Number of Products by Stage and Molecule Type, H2 2015
- Neuromyelitis Optica (Devic’s Syndrome) Therapeutics - Recent Pipeline Updates, H2 2015
- Neuromyelitis Optica (Devic’s Syndrome) - Dormant Projects, H2 2015
- List of Figures
- Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H2 2015
- Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome) - Comparative Analysis, H2 2015
- Number of Products under Development by Companies, H2 2015
- Comparative Analysis by Clinical Stage Development, H2 2015
- Comparative Analysis by Early Stage Products, H2 2015
- Assessment by Monotherapy Products, H2 2015
- Number of Products by Top 10 Targets, H2 2015
- Number of Products by Stage and Top 10 Targets, H2 2015
- Number of Products by Top 10 Mechanism of Actions, H2 2015
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
- Number of Products by Top 10 Routes of Administration, H2 2015
- Number of Products by Stage and Top 10 Routes of Administration, H2 2015
- Number of Products by Top 10 Molecule Types, H2 2015
- Number of Products by Stage and Top 10 Molecule Types, H2 2015
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBookOther tasks
